Healthcare provider profile · identity verified

Edward C Da Veiga, MD

Internal Medicine · ABINGTON, PA · NPI 1881773067

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	293	77
Gabapentin	Gabapentin	226	45
Amlodipine Besylate	Amlodipine Besylate	168	48
Omeprazole	Omeprazole	159	33
Fluticasone Propionate	Fluticasone Propionate	141	41
Metoprolol Succinate	Metoprolol Succinate	132	26
Albuterol Sulfate Hfa	Albuterol Sulfate	122	29
Levothyroxine Sodium	Levothyroxine Sodium	110	21
Metformin Hcl	Metformin Hcl	96	22
Losartan Potassium	Losartan Potassium	95	29
Famotidine	Famotidine	75	17
Lisinopril	Lisinopril	70	18
Pantoprazole Sodium	Pantoprazole Sodium	70	18
Carvedilol	Carvedilol	69	20
Trulicity	Dulaglutide	67	17
Trazodone Hcl	Trazodone Hcl	65	14
Valsartan	Valsartan	54	14
Furosemide	Furosemide	48	11
Hydrochlorothiazide	Hydrochlorothiazide	48	13
Metformin Hcl Er	Metformin Hcl	47	15
Ibuprofen	Ibuprofen	46	12
Duloxetine Hcl	Duloxetine Hcl	45	11
Tamsulosin Hcl	Tamsulosin Hcl	43	13
Mirtazapine	Mirtazapine	42	suppressed
Montelukast Sodium	Montelukast Sodium	42	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	40	suppressed
Diclofenac Sodium	Diclofenac Sodium	39	suppressed
Alprazolam	Alprazolam	38	suppressed
Chlorthalidone	Chlorthalidone	38	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	38	12
Eliquis	Apixaban	37	suppressed
Nifedipine Er	Nifedipine	37	suppressed
Oxycodone Hcl	Oxycodone Hcl	37	15
Farxiga	Dapagliflozin Propanediol	35	suppressed
Naproxen	Naproxen	34	suppressed
Allopurinol	Allopurinol	33	suppressed
Celecoxib	Celecoxib	33	suppressed
Ventolin Hfa	Albuterol Sulfate	33	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	12
Sertraline Hcl	Sertraline Hcl	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	suppressed
Clonazepam	Clonazepam	26	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	12
Meloxicam	Meloxicam	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	suppressed
Topiramate	Topiramate	23	suppressed
Baclofen	Baclofen	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Lidocaine	Lidocaine	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Bumetanide	Bumetanide	16	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Glipizide Er	Glipizide	16	suppressed
Incruse Ellipta	Umeclidinium Bromide	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Torsemide	Torsemide	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Ammonium Lactate	Ammonium Lactate	15	suppressed
Easy Comfort Pen Needle	Pen Needle, Diabetic	15	suppressed
Risperidone	Risperidone	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Acebutolol Hcl	Acebutolol Hcl	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Mupirocin	Mupirocin	13	12
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Oxycontin	Oxycodone Hcl	11	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed
Prednisone	Prednisone	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error